TAK-901 is primarily investigated for its potential in cancer treatment, particularly as an inhibitor of specific kinases involved in cell cycle regulation. It targets Aurora kinases, which play a critical role in mitosis, making it a promising candidate for disrupting the proliferation of cancer cells. Research focuses on its application in treating various malignancies, including solid tumors and hematologic cancers. Its mechanism of action involves inducing cell cycle arrest and apoptosis in rapidly dividing cells, offering a therapeutic strategy for patients with limited treatment options. Clinical trials are ongoing to evaluate its efficacy, safety, and potential as part of combination therapies.